Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1beta , and IFN-gamma. Pralnacasan is an effective, non-peptide, and orally active interleukin-1beta converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment.